Marine-derived compound shows promise against deadly brain eating amoeba (opens in a new tab)

news-medical.net · 2026-10-26

Short answerEvidenceSource

Short answer

Source study unconfirmed

Study not confirmed.

The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

40 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail

The story

Marine-derived compound shows promise against deadly brain eating amoeba

news-medical.net · 2026-10-26

The story’s checkable claims.

Read the original story

NewsLink checks it

No single source study could be confirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

View article claims

Search result

Source study unconfirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

Also referencedpresented as the new finding
Antiamoebic Activity of Rutamycin B and Inhibition of Naegleria fowleri F1FO ATP Synthase Activity
Publisher (opens in a new tab)

Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Reading mode

Scan verdicts. Open evidence only when needed.

Claim 1 of 4Not checkedResearchers at the University of California San Diego have isolated a marine-derived compound that may provide a faster, more effective way to stop the parasite Naegleria fowleri.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 4Not checkedRutamycin B, a compound isolated from a marine bacterium, demonstrates significant potency at low concentrations against multiple clinical strains of N. fowleri and reaches full potency within just four hours, outpacing amphotericin B.View evidenceHide evidence

As statedfull potency within four hours versus 16 hours

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 4Not checkedThe compound was reported to be 200 to 300 times more lethal to the parasite than to human cells and to work by shutting down an enzyme the parasite uses to produce energy.View evidenceHide evidence

As stated200 to 300 times more lethal to the parasite than to human cells

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 4Not checkedWhen combined with the current standard treatment, the researchers found they could achieve the same results using as little as 3% to 10% of the original dose of rutamycin B, and the team plans future studies to test blood-brain barrier penetration and efficacy in live disease models.View evidenceHide evidence

As statedas little as 3% to 10% of the original dose

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results